4.6 Article

Diagnostic performances of clinical laboratory tests using Triton X-100 to reduce the biohazard associated with routine testing of Ebola virus-infected patients

Journal

CLINICAL CHEMISTRY AND LABORATORY MEDICINE
Volume 53, Issue 12, Pages 1967-1973

Publisher

WALTER DE GRUYTER GMBH
DOI: 10.1515/cclm-2015-0119

Keywords

clinical chemistry; coagulation; Ebola; haematology; Triton

Funding

  1. Ministero della Salute of Italy (Istituto Nazionale per le Malattie Infettive I.R.C.C.S. Lazzaro Spallanzani, Ricerca Corrente)

Ask authors/readers for more resources

Background: Ebola virus, an enveloped virus, is the cause of the largest and most complex Ebola virus disease (EVD) outbreak in West Africa. Blood or body fluids of an infected person may represent a biohazard to laboratory workers. Laboratory tests of virus containing specimens should be conducted in referral centres at biosafety level 4, but based on the severity of clinical symptoms, basic laboratories might be required to execute urgent tests for patients suspected of EVD. The aim of this work was to compare the analytical performances of laboratory tests when Triton X-100, a chemical agent able to inactivate other enveloped viruses, was added to specimens. Methods: Results of clinical chemistry, coagulation and haematology parameters on samples before and after the addition of 0.1% (final concentration) of Triton X-100 and 1 h of incubation at room temperature were compared. Results: Overall, results showed very good agreement by all statistical analyses. Triton X-100 at 0.1% did not significantly affect the results for the majority of the analytes tested. Conclusions: Triton X-100 at 0.1% can be used to reduce the biohazard in performing laboratory tests on samples from patients with EVD without affecting clinical decisions.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Gastroenterology & Hepatology

Coordinated cellular and humoral immune responses after two-dose SARS-CoV2 mRNA vaccination in liver transplant recipients

Gianpiero D'Offizi, Chiara Agrati, Ubaldo Visco-Comandini, Concetta Castilletti, Vincenzo Puro, Paola Piccolo, Marzia Montalbano, Silvia Meschi, Eleonora Tartaglia, Chiara Sorace, Sara Leone, Daniele Lapa, Germana Grassi, Delia Goletti, Giuseppe Ippolito, Francesco Vaia, Giuseppe Maria Ettorre, Raffaella Lionetti

Summary: Limited data are available on risks and benefits of anti-SARS-CoV2 vaccination in solid organ transplant recipients, and weaker responses have been described. Liver transplant recipients showed lower response rates compared with controls in both humoral and cellular arms; shorter time since transplantation and multi-drug immunosuppressive regimen containing mycophenolate mofetil were predictive of reduced response to vaccination. Specific antibody and cytokine production, though reduced, were highly correlated in transplant recipients.

LIVER INTERNATIONAL (2022)

Article Clinical Neurology

Humoral- and T-Cell Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies

Carla Tortorella, Alessandra Aiello, Claudio Gasperini, Chiara Agrati, Concetta Castilletti, Serena Ruggieri, Silvia Meschi, Giulia Matusali, Francesca Colavita, Chiara Farroni, Gilda Cuzzi, Eleonora Cimini, Eleonora Tartaglia, Valentina Vanini, Luca Prosperini, Shalom Haggiag, Simona Galgani, Maria Esmeralda Quartuccio, Andrea Salmi, Federica Repele, Anna Maria Gerarda Altera, Flavia Cristofanelli, Alessandra D'Abramo, Nazario Bevilacqua, Angela Corpolongo, Vincenzo Puro, Francesco Vaia, Maria Rosaria Capobianchi, Giuseppe Ippolito, Emanuele Nicastri, Delia Goletti

Summary: This study evaluated the immune-specific response after full SARS-CoV-2 vaccination in patients with multiple sclerosis (MS) treated with different disease-modifying drugs. The results showed that mRNA vaccines induced both humoral and cell-mediated specific immune responses against viral spike proteins in the majority of patients with MS. These findings have important implications for promoting vaccination in all MS patients.

NEUROLOGY (2022)

Article Cell Biology

GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults

Simone Lanini, Stefania Capone, Andrea Antinori, Stefano Milleri, Emanuele Nicastri, Roberto Camerini, Chiara Agrati, Concetta Castilletti, Federica Mori, Alessandra Sacchi, Giulia Matusali, Roberta Gagliardini, Virginia Ammendola, Eleonora Cimini, Fabiana Grazioli, Laura Scorzolini, Federico Napolitano, Maria M. Plazzi, Marco Soriani, Aldo De Luca, Simone Battella, Andrea Sommella, Alessandra M. Contino, Federica Barra, Michela Gentile, Angelo Raggioli, Yufang Shi, Enrico Girardi, Markus Maeurer, Maria R. Capobianchi, Francesco Vaia, Mauro Piacentini, Guido Kroemer, Alessandra Vitelli, Stefano Colloca, Antonella Folgori, Giuseppe Ippolito

Summary: Safe and effective COVID-19 vaccines are crucial for ending the pandemic. A vaccine called GRAd-COV2, based on a gorilla adenovirus and expressing the spike protein of SARS-CoV-2, has been evaluated for safety and immunogenicity in healthy younger and older adults.

SCIENCE TRANSLATIONAL MEDICINE (2022)

Article Virology

In Acute Dengue Infection, High TIM-3 Expression May Contribute to the Impairment of IFNγ Production by Circulating Vδ2 T Cells

Eleonora Cimini, Germana Grassi, Alessia Beccacece, Rita Casetti, Concetta Castilletti, Maria Rosaria Capobianchi, Emanuele Nicastri, Chiara Agrati

Summary: Gamma delta T cells play a role in eliminating pathogens and infected/tumoral cells. Their role in Dengue Viral Infection (DENV) is not fully understood. This study characterized V delta 2 T cells in DENV patients and found that DENV infection reduced their frequency and increased activation and exhaustion markers. The functionality of V delta 2 T cells, especially IFN-gamma production, was also affected. Further studies are needed to understand the clinical impact of gamma delta T cell impairment in disease severity and their antiviral and immunoregulatory activities.

VIRUSES-BASEL (2022)

Article Immunology

Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study

Paolo Corradini, Chiara Agrati, Giovanni Apolone, Alberto Mantovani, Diana Giannarelli, Vincenzo Marasco, Veronica Bordoni, Alessandra Sacchi, Giulia Matusali, Carlo Salvarani, Pier Luigi Zinzani, Renato Mantegazza, Fabrizio Tagliavini, Maria Teresa Lupo-Stanghellini, Fabio Ciceri, Silvia Damian, Antonio Uccelli, Daniela Fenoglio, Nicola Silvestris, Fausto Baldanti, Giulia Piaggio, Gennaro Ciliberto, Aldo Morrone, Franco Locatelli, Valentina Sinno, Maria Rescigno, Massimo Costantini

Summary: This study investigated the immune response to the SARS-CoV-2 vaccine in patients with tumors and immune disorders. The results showed that immunosuppressive treatment was a risk factor for a low humoral response, while the booster dose improved both humoral and T-cell responses.

CLINICAL INFECTIOUS DISEASES (2023)

Article Chemistry, Medicinal

Virological and Immunological Outcomes of an Intensified Four-Drug versus a Standard Three-Drug Antiretroviral Regimen, Both Integrase Strand Transfer Inhibitor-Based, in Primary HIV Infection

Annalisa Mondi, Carmela Pinnetti, Patrizia Lorenzini, Maria Maddalena Plazzi, Isabella Abbate, Marta Camici, Chiara Agrati, Elisabetta Grilli, Francesca Gili, Rozenn Esvan, Nicoletta Orchi, Gabriella Rozera, Alessandra Amendola, Federica Forbici, Caterina Gori, Roberta Gagliardini, Rita Bellagamba, Adriana Ammassari, Stefania Cicalini, Maria Rosaria Capobianchi, Andrea Antinori

Summary: Both a four-drug and a three-drug regimen for primary HIV infection showed comparable viroimmunological responses.

PHARMACEUTICALS (2022)

Article Virology

SARS-CoV-2 Specific Immune Response and Inflammatory Profile in Advanced HIV-Infected Persons during a COVID-19 Outbreak

Alessandra Vergori, Antonio Boschini, Stefania Notari, Patrizia Lorenzini, Concetta Castilletti, Francesca Colavita, Giulia Matusali, Eleonora Tartaglia, Roberta Gagliardini, Andrea Boschi, Eleonora Cimini, Markus Maeurer, Pierluca Piselli, Leila Angeli, Andrea Antinori, Chiara Agrati, Enrico Girardi

Summary: The study aimed to describe the clinical and immunological outcomes of advanced HIV patients with a SARS-CoV-2 outbreak. The results suggest that HIV infection does not negatively impact COVID-19-related inflammatory state and immunity.

VIRUSES-BASEL (2022)

Article Virology

Evidence of Maternal Antibodies Elicited by COVID-19 Vaccination in Amniotic Fluid: Report of Two Cases in Italy

Francesca Colavita, Alessandra Oliva, Aurora Bettini, Andrea Antinori, Enrico Girardi, Concetta Castilletti, Francesco Vaia, Giuseppina Liuzzi

Summary: A study has found that antibodies produced after COVID-19 vaccination can pass through the placenta and provide passive immunity to newborns. Understanding the maternal response to vaccination and the persistence of antibodies in infants is critical for optimizing maternal immunization regimens.

VIRUSES-BASEL (2022)

Article Infectious Diseases

External quality assessment of SARS-CoV-2 serology in European expert laboratories, April 2021

Ramona Mogling, Francesca Colavita, Johan Reimerink, Angeliki Melidou, Katrin Leitmeyer, Maria Keramarou, Daniele Lapa, Massimo Francalancia, Jean-Luc Murk, Ann Vossen, Fabrizio Carletti, Boris Hogema, Adam Meijer, Liesbet Deprez, Antonino di Caro, Concetta Castilletti, Chantal Bem Reusken

Summary: This study aimed to assess the capability of European reference laboratories in detecting SARS-CoV-2 antibodies in COVID-19 sero-epidemiological studies. The study found that most laboratories were able to accurately determine past SARS-CoV-2 infections through antibody detection, with certain specific test methods performing better.

EUROSURVEILLANCE (2022)

Article Multidisciplinary Sciences

Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV

Alessandra Vergori, Alessandro Cozzi Lepri, Stefania Cicalini, Giulia Matusali, Veronica Bordoni, Simone Lanini, Silvia Meschi, Roberta Iannazzo, Valentina Mazzotta, Francesca Colavita, Ilaria Mastrorosa, Eleonora Cimini, Davide Mariotti, Lydia De Pascale, Alessandra Marani, Paola Galli, AnnaRosa Garbuglia, Concetta Castilletti, Vincenzo Puro, Chiara Agrati, Enrico Girardi, Francesco Vaia, Andrea Antinori

Summary: HIV-infected individuals showed a strong humoral response after the third dose of a SARS-CoV-2 vaccine, while their cell-mediated immunity remained stable. This study highlights the usefulness of a third vaccine dose in people living with HIV who are on suppressive antiretroviral therapy.

NATURE COMMUNICATIONS (2022)

Editorial Material Infectious Diseases

Polio is back? The risk of poliomyelitis recurrence globally, and the legacy of the severe acute respiratory syndrome coronavirus 2 pandemic

Concetta Castilletti, Maria Rosaria Capobianchi

CLINICAL MICROBIOLOGY AND INFECTION (2023)

Letter Infectious Diseases

People with asymptomatic or unrecognised infection potentially contribute to monkeypox virus transmission

Silvia Accordini, Maddalena Cordioli, Elena Pomari, Evelina Tacconelli, Concetta Castilletti

LANCET MICROBE (2023)

Article Medicine, General & Internal

Subjects who developed SARS-CoV-2 specific IgM after vaccination show a longer humoral immunity and a lower frequency of infection

Chiara Piubelli, Alessandra Ruggiero, Lucia Calciano, Cristina Mazzi, Concetta Castilletti, Natalia Tiberti, Sara Caldrer, Matteo Verze, Silvia Stefania Longoni, Simone Accordini, Zeno Bisof, Donato Zipeto

Summary: The development of SARS-CoV-2-specific IgM after vaccination is associated with higher levels of SARS-CoV-2 neutralizing IgG. This study aims to assess whether IgM development is also associated with longer-lasting immunity. The results show that IgM development after vaccination is associated with higher levels of IgG antibodies in the short and long term, and most individuals who developed IgM antibodies did not experience infection, suggesting a lower risk of infection.

EBIOMEDICINE (2023)

Article Medicine, General & Internal

Evaluation of a ddPCR Commercial Assay for the Absolute Quantification of the Monkeypox Virus West Africa in Clinical Samples

Elena Pomari, Antonio Mori, Silvia Accordini, Annalisa Donini, Maddalena Cordioli, Evelina Tacconelli, Concetta Castilletti

Summary: A commercial ddPCR assay was evaluated for the detection of the West African clade of monkeypox virus (MPXV) in clinical samples. The assay showed good performance for skin lesions and rectal swabs.

DIAGNOSTICS (2023)

No Data Available